The market has been high on Taysha Gene Therapies Inc (TSHA) stock recently. TSHA gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.
Taysha Gene Therapies Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on TSHA!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With TSHA Stock Today?
Taysha Gene Therapies Inc (TSHA) stock is trading at $2.23 as of 12:35 PM on Monday, Nov 28, a drop of -$0.10, or -4.29% from the previous closing price of $2.33. The stock has traded between $2.18 and $2.34 so far today. Volume today is less active than usual. So far 170,913 shares have traded compared to average volume of 4,923,841 shares.
To see InvestorsObserver's Sentiment Score for Taysha Gene Therapies Inc click here.
More About Taysha Gene Therapies Inc
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Click Here to get the full Stock Report for Taysha Gene Therapies Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
